Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for antipsychotic-induced weight gain in severe mental illness in South Asia
ISRCTN23496771Phase 4Recruiting
- Sponsor
- University of York
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in antipsychotic-induced weight gain (AIWG) comparing Metformin XR with Placebo (2 arms). Primary endpoint: Change in body weight. Started Feb 2026; status: recruiting.
02
Drugs
metformin
03
Conditions
antipsychotic-induced weight gain (AIWG)
Beyond the preview
Go deeper on ISRCTN23496771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN23496771.